Plasmacure raises series A round of funding
Dutch med-tech start-up company Plasmacure, developing a chronic wound healing device Plasoma, closed a series A round of funding. The funding was raised with private investors, NextGen Ventures and East Netherlands Development Agency - Oost NL. NextGen Ventures is a fund built primarily on investments by the healthcare insurers Menzis and Friesland Zorgverzekeraar.
Plasmacure will use the investment to get CE mark and introduce the product to the market. The first focus is on diabetic foot wounds. This funding will support Plasmacure in developing the device for home use, and for treating other types of wounds.
“This funding is very important for us, because it will enable us to bring the device to the market, to the people, who need it and for whom there is no real help at this moment. We realize that we can really start helping these people and this feels great” – said the CEO and founder of the company, Bas Zeper.
The primary reason for Oost NL to invest in Plasmacure is that it makes healthcare more affordable. Treating persistently open wounds costs the Dutch healthcare budget €2 billion. Pieter Rhemrev, manager of the business unit Capital at Oost NL, says, “Plasmacure is handy, takes very little time to apply and is painless. It clearly advances the quality of life for the patient. With this investment we are promoting result-oriented healthcare".
Plasmacure has already showed great potential and very positive results after the first clinical trial at VU Medical Center Amsterdam. This study with participation of 20 patients demonstrated that more than half of the wounds reduced in size and two wounds (10%) healed completely during the two weeks treatment period.
Founded in 2014, the Dutch start-up company Plasmacure is developing its first product - Plasoma. With this device the company aims to heal chronic wounds and decrease risk of amputation, thereby increase quality of life for patients.
415 million people are diagnosed with diabetes worldwide and this number rises every year. 15% of people with diabetes develop a foot ulcer, 2-4% will face an amputation because of infections.
First initiated by TU/e, Plasoma was further developed by the CEO and founder of the company Bas Zeper. Quick and painless solution Plasoma consists of an electronic pad that creates a cold plasma in the wound and a pulser that sends the electric current to the pad. When applied to the wound the cold plasma kills the bacteria and stimulates healing.
Plasmacure collaborates with a number of partners. On the product development side the company cooperates with KeyTec, TSG and Relitech. Plasmacure also works closely with Diabetes Fonds, VUmc and TU/e.
Plasmacure is the winner of the Blue Tulip, the prestigious Accenture Innovation Award in the category Health and Wellbeing sector.